Enozertinib clinical trials
Also written ORIC-114.
How each study uses enozertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the enozertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ORIC-114
- 2
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
Who runs them
Industry 3 · Other 0
ORIC Pharmaceuticals (3)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test enozertinib.
- Dec 2026ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCPhase 1 · ORIC Pharmaceuticals
- Jun 2027Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationPhase 1/2 · ORIC Pharmaceuticals
Studies
Open first, then newest update. How each study uses enozertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationRecruitingPhase 1/2ORIC PharmaceuticalsNCT05315700Written as ORIC-114
- ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCRecruitingPhase 1ORIC PharmaceuticalsNCT06816992Written as ORIC-114 Dose 1 + amivantamab
- Effect of Food on the Pharmacokinetics of ORIC-114CompletedPhase 1ORIC PharmaceuticalsNCT06012721Written as ORIC-114
Codes
What other systems call enozertinib · ClinicalTrials.gg INT016371
- UNII (FDA) DU24UP8R94ENOZERTINIBConfirmed FDA, Wikidata
- Wikidata Q140529159enozertinibConfirmed FDA, Wikidata
- NCI Thesaurus C187334EnozertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DU24UP8R94 | ENOZERTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q140529159 | enozertinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C187334 | Enozertinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.